SEC 13F Intelligence

Managers / Q2 2025 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$151M
Q2 2025
Positions
94
Filings on Record
30
2019–present window
Filed
Aug 14, 2025
original filing

Summary

Sectoral Asset Management Inc reported $151M in U.S.-listed holdings across 94 positions for Q2 2025.

Its largest position, LENZ, represents 18.9% of the portfolio.

Compared with Q1 2025, the fund opened 25 new positions and exited 15.

Portfolio Metrics

Turnover
+18.3%
vs prior filed quarter
Top-10 Concentration
+42.3%
share of reported value
Largest Position
+18.9%
Lenz Therapeutics
New / Exited
25 / 15
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 89.9%ADR: 6.2%Other: 3.8%
  • Common Stock · 89.9% · $136M
  • ADR · 6.2% · $9M
  • Other · 3.8% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MBXMBX BIOSCIENCES INCNEW+191.8K191.8K+$2M$2M
PVLAPALVELLA THERAPEUTICNEW+95.6K95.6K+$2M$2M
REPLREPLIMUNE GROUP INCNEW+231.7K231.7K+$2M$2M
SLDBSOLID BIOSCIENCESNEW+421.6K421.6K+$2M$2M
RAPPRAPPORT THERAPEUTICSNEW+179.9K179.9K+$2M$2M
ZBIOZENAS BIOPHARMA INCNEW+210.6K210.6K+$2M$2M
VTYXUSDVENTYX BIOSCIENCESNEW+931.6K931.6K+$2M$2M
TECXTECTONIC THERAPEUTICNEW+99.0K99.0K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2025

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LENZLENZ THERAPEUTICShistory →COM18.91%$29M977.2K
2LLYELI LILLY & COhistory →COM4.62%$7M9.0K
3UNHUNITEDHEALTH GRP INChistory →COM3.45%$5M16.7K
4MLYSMINERALYS THERAPEUTIhistory →COM3.42%$5M382.4K
5CTNMCONTINEUM THERAPEUTIhistory →CL A2.10%$3M800.8K
6AMGNAMGEN INChistory →COM2.08%$3M11.3K
7VRTXVERTEX PHARMAhistory →COM2.04%$3M6.9K
8JNJJOHNSON & JOHNSONhistory →COM1.95%$3M19.3K
9ISRGINTUITIVE SURGIC INChistory →COM NEW1.88%$3M5.3K
10ABBVABBVIE INChistory →COM1.81%$3M14.8K
11ORICORIC PHARMACEUTICAhistory →COM1.55%$2M231.5K
12BSXBOSTON SCIENTIFIChistory →COM1.50%$2M21.1K
13ARGXARGENX SE SPNhistory →SP ADR1.49%$2M4.1K
14MBXMBX BIOSCIENCES INChistory →COM1.45%$2M191.8K
15GILDGILEAD SCIENCES INChistory →COM1.44%$2M19.7K
16PVLAPALVELLA THERAPEUTIChistory →COM1.42%$2M95.6K
17REPLREPLIMUNE GROUP INChistory →COM1.42%$2M231.7K
18RCUSARCUS BIOSCIENCEShistory →COM1.38%$2M257.3K
19DHRDANAHER CORPhistory →COM1.38%$2M10.6K
20ABTABBOTT LABShistory →COM1.36%$2M15.2K
21SLDBSOLID BIOSCIENCEShistory →COM NEW1.36%$2M421.6K
22RAPPRAPPORT THERAPEUTICShistory →COM1.35%$2M179.9K
23ZBIOZENAS BIOPHARMA INChistory →COM1.35%$2M210.6K
24VTYXUSDVENTYX BIOSCIENCEShistory →COM1.32%$2M931.6K
25TECXTECTONIC THERAPEUTIChistory →COM1.30%$2M99.0K
26BCAXBICARA THERAPEUTICShistory →COM1.24%$2M201.4K
27PFEPFIZER INChistory →COM1.23%$2M77.2K
28ONCBEONE MEDICINES LTDhistory →SP ADR1.23%$2M7.7K
29KURAKURA ONCOLOGY INChistory →COM1.23%$2M323.6K
30TOURMALINE BIO INCCOM1.23%$2M116.5K
31ANABANAPTYSBIO INChistory →COM1.23%$2M83.9K
32TILINSTIL BIO INChistory →COM NEW1.19%$2M86.2K
33IMMATICS NVSHS1.18%$2M332.3K
34BNTXBIONTECH SEhistory →SP ADR1.14%$2M16.2K
35MRKMERCK & CO INChistory →COM1.10%$2M20.9K
36TMOTHERMO FISHER SCIhistory →COM1.04%$2M3.9K
37SYKSTRYKER CORPhistory →COM1.02%$2M3.9K
38IM8NINSMED INCCOM PAR $.010.99%$1M14.9K
39REGNREGENERON PHARMCTCLSCOM0.96%$1M2.8K
40SMMTSUMMIT THERAPEUTICSCOM0.92%$1M65.2K
41AZNNASTRAZENECASP ADR0.86%$1M18.6K
42BMRNBIOMARIN PHARMAC INCCOM0.85%$1M23.5K
43EWEDWARDS LIFESCIENCECOM0.77%$1M15.0K
44DC4DEXCOM INCCOM0.76%$1M13.2K
45SPRYARS PHARMACEUTICALSCOM0.76%$1M65.8K
46ALNYALNYLAM PHARMACUETCLCOM0.72%$1M3.3K
47GPCRSTRUCTURE THERAPEUSP ADR0.70%$1M51.4K
48VERAVERA THERAPEUTICSCL A0.64%$975,80841.4K
49MERUS B VCOM0.54%$824,50515.7K
50GMEDGLOBUS MED INCCL A0.53%$796,77013.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.